市场概况

The global hepatocellular carcinoma (HCC) treatment market is projected to reach USD 8.05 十亿 2029, growing at a CAGR of 13.4% 从 2023 到 2029. HCC is the most common type of liver cancer, 占 89% of cases. It has a low survival rate of less than 5% and is influenced by factors like hepatitis, aflatoxin exposure, and liver cirrhosis. The HCC treatment pipeline includes over 155 assets, with PD-1 and PD-L1 inhibitors being dominant. There are 220 clinical trials for HCC treatment, with the US leading. Biologics targeting PD-1 and PD-L1 have gained traction. The introduction of five new agents is expected to drive market growth. Therapeutic agents targeting PD-1 and PD-L1 have shown effectiveness in HCC, and innovation and technological advancements are expected to improve outcomes.

该报告涵盖了市场规模和增长, 分割, 竞争格局, trends and strategies for global hepatocellular carcinoma treatment market. 它提供了对市场的定量分析，使利益相关者能够利用当前的市场机会. 该报告还根据市场趋势和主要竞争对手的方法确定了最重要的机会和战略细分市场.

市场细分

The market is segmented based on various factors, including drug class, gender type, 年龄阶层, and geography.
Drug class: chemotherapy, targeted therapy
Gender: 男人, 女性
年龄阶层: 以下 29 年, 30-49 年, 50+ 年

Segmentation by Geography
North America – US
Europe – Germany, 法国, 英国, 意大利, 西班牙
APAC – 中国, 日本

Chemotherapeutic drugs will remain dominant in the global HCC therapeutics market, but targeted therapies are expected to grow rapidly. The approval of biologics like Tecentriq (Atezolizumab) will drive the HCC treatment market. Research into novel mechanisms of action (MOAs) aims to address treatment non-response. The launch of new drugs targeting moderate-to-severe patients will drive market growth. Biologics targeting PD-1 and PD-L1 are gaining popularity.

Men will have a significant share in the HCC treatment market due to higher prevalence. 这 50 years and above age group dominates the market.

The United States is the leading market due to affordability, awareness, 和技术. China will experience fast growth due to improved healthcare access and expenditure. The US holds a significant market share of 48.3% in the HCC treatment market among the eight major markets.

Competitive Landscape

The global HCC treatment market has numerous companies offering generic and patented drugs. The FDA approved Nivolumab, Keytruda, and Tecentriq for HCC treatment. Biologics and targeted therapies are changing the treatment landscape. Key players include Abbisko Therapeutics Co., 有限公司, Advenchen Laboratories, 有限责任公司。, Akeso, 公司, 阿斯利康公司, 拜耳公司, BeiGene, 有限公司, 百时美施贵宝公司, Eli Lilly and Company, Exelixis, 公司, F. 罗氏霍夫曼公司, Genoscience Pharma SAS, Innovent Biologics, 公司, Jiangsu Hengrui Pharmaceuticals Co., 有限公司, 默克 & 公司。, 公司, Novra Technologies Inc., 辉瑞公司, 赛诺菲公司, Shanghai Henlius Biotech Inc., Surface Oncology, 公司, Suzhou Zelgen Biopharmaceuticals Co., 有限公司, TaiRx, 公司, Virogin Biotech Ltd., and Yiviva Inc. These companies invest in research, collaborations, 收购, and innovation to compete in the market.

Recent Industry Developments

Roche announced in May 2020 that the Food and Drug Administration approved the use of atezolizumab in combination with bevacizumab (Tecentriq) for the treatment of unresectable or metastatic hepatocellular carcinoma in patients without prior systemic therapy. This approval was based on findings from the international IMbrave150 (NCT03434379) trial, which involved patients with locally advanced unresectable or metastatic hepatocellular carcinoma who had not received prior systemic therapy.

In May 2019, Eli Lilly and Company announced that the Food and Drug Administration approved ramucirumab (Cyramza) as a standalone treatment for hepatocellular carcinoma (HCC) in patients with an alpha-fetoprotein (AFP) level of ≥ 400 ng/mL who had previously been treated with sorafenib. This approval was based on data from the REACH-2 (NCT02435433) study, a double-blind, placebo-controlled, multinational trial conducted in 292 patients with advanced HCC and AFP levels ≥ 400 ng/mL who had experienced disease progression on or after sorafenib treatment or were intolerant to it.

报告范围

To analyze and forecast the market size of the global hepatocellular carcinoma treatment market.
To classify and forecast the global hepatocellular carcinoma treatment market based on drug class, gender, 年龄阶层, geography.
To identify drivers and challenges for the global hepatocellular carcinoma treatment market.
检查合并等竞争性发展 & 收购, 协议, 合作与伙伴关系, ETC。, in the global hepatocellular carcinoma treatment market.
To identify and analyze the profile of leading players operating in the global hepatocellular carcinoma treatment market.

为什么选择这份报告

Gain a reliable outlook of the global hepatocellular carcinoma treatment market forecasts from 2023 到 2029 跨场景.
确定投资的增长领域.
通过公司简介和市场数据领先于竞争对手.
Excel 格式的跨场景分析易用性的市场预估.
三个月的战略咨询和研究支持.
为单用户许可证提供打印验证.